Phathom Pharmaceuticals Delivers Record Q2 2026 Results, Achieves Operating Profitability (Ex-Stock Comp), and Updates Guidance
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has released its financial results for the second quarter ended June 30, 2026, alongside a comprehensive business update. The company, focused on gastrointestinal (GI) disease therapies, reported a number of significant operational and financial milestones that are likely to attract the attention of investors and potentially impact share value.
Key Highlights for Investors
- Record Net Revenues: Q2 2026 net revenues reached \$74.3 million, an 88% year-over-year increase and a 27% rise from Q1 2026. This growth reflects the successful execution of Phathom’s commercial strategy and the growing adoption of VOQUEZNA®.
- Operating Profitability Achieved (Ex-Stock Compensation): For the first time, Phathom reported operating profitability excluding non-cash stock-based compensation—an important inflection point for the company as it transitions to a sustainable business model.
- Cost Reduction: Q2 operating expenses were reduced by 33% year-over-year to \$63.1 million, driven by lower commercial promotional spend, reduced personnel costs, and disciplined cost management.
- Strong Prescription Growth: Approximately 1.7 million total VOQUEZNA prescriptions have been filled to date. Q2 2026 alone saw about 325,000 prescriptions filled, up 88% year-over-year and 21% quarter-over-quarter. Notably, 64% of these were covered prescriptions, reflecting improved reimbursement and market access.
- Pipeline Developments:
- Initiation of a Phase 3 clinical trial for as-needed (PRN) dosing of VOQUEZNA in Non-Erosive GERD (NERD) is planned for Q4 2026, aimed at expanding the label and market opportunity.
- Completion of enrollment in the Phase 2 pHalcon-EoE-201 trial for Eosinophilic Esophagitis (EoE), with topline results expected in Q4 2026. Positive data could support discussions with the FDA for further development, including pediatrics, and potentially extend regulatory exclusivity by six months.
- Balance Sheet Strength: Cash and cash equivalents stood at \$182.5 million as of June 30, 2026, up from \$129.9 million at year-end 2025. Management believes current cash and future anticipated cash flows are sufficient to fund operations and meet all existing debt obligations without raising additional capital.
- Updated 2026 Financial Guidance:
- Net Revenue: Now forecast at \$310–325 million (down from previous \$320–345 million).
- Non-GAAP Operating Expenses (Ex-Stock Comp): Expected to be \$235–245 million (narrowed from prior \$235–255 million).
- Operating Profitability (Ex-Stock Comp): Still expected for the remainder of 2026 and full year.
- Gross-to-Net Discount: Maintained at 55–59%.
- Gross Margin: Maintained at approximately 80%.
Detailed Financial Results
- Revenue: \$74.3 million in Q2 2026 (up from \$39.5 million in Q2 2025).
- R&D Expenses: \$7.8 million in Q2 2026 (down from \$9.1 million in Q2 2025).
- SG&A Expenses: \$55.3 million in Q2 2026 (down from \$85.3 million in Q2 2025), primarily due to reduced direct-to-consumer promotional spend and personnel costs.
- Net Loss: GAAP net loss of \$17.6 million in Q2 2026 (compared to \$75.8 million in Q2 2025). Non-GAAP adjusted net loss was nearly breakeven at \$0.1 million, a dramatic improvement from \$56.5 million in the prior year period.
- Cash Position: \$182.5 million as of June 30, 2026.
Business and Pipeline Updates
- VOQUEZNA Performance and Market Opportunity:
- VOQUEZNA prescriptions and covered lives have grown rapidly, validating the company’s pivot to focus on gastroenterologists.
- Management reiterates belief in VOQUEZNA’s potential to reach \$1 billion in annual revenue from gastroenterology providers, with an additional \$1 billion annual opportunity via primary care expansion.
- Clinical Pipeline:
- Phase 3 As-Needed (PRN) GERD Study: The as-needed use program could significantly expand the addressable market, especially for patients preferring non-daily therapy.
- EoE (Eosinophilic Esophagitis): Topline Phase 2 results expected Q4 2026; could lead to expanded indications and extended exclusivity if positive.
Important Shareholder Considerations & Potential Price Sensitive Information
- Achievement of Operating Profitability (Ex-Stock Comp) for the First Time: This milestone marks a turning point for Phathom and may shift investor sentiment toward a more sustainable, growth-focused outlook.
- Significant Reductions in Expenses and Cash Burn: Expense discipline has sharply reduced losses and improved cash flow outlook, mitigating risks of future dilutive capital raises.
- Updated, Slightly Lower Revenue Guidance: The modest reduction in full-year net revenue guidance may be viewed as a conservative move, but still reflects robust year-on-year growth and a strong commercial launch trajectory.
- Upcoming Clinical Catalysts: Initiation of a pivotal Phase 3 trial and the release of Phase 2 EoE data in Q4 2026 are meaningful events that could impact future regulatory strategy, market size, and exclusivity.
- Sufficient Cash to Cover Obligations Without Additional Financing: This provides near-term financial security and reduces equity dilution risk.
Risks and Forward-Looking Statements
Phathom’s outlook remains subject to a range of risks, including but not limited to: market acceptance and competitive dynamics for VOQUEZNA, regulatory and reimbursement challenges, ongoing clinical trial results, and the potential need for additional capital if cash flows fall short of expectations. Investors should review the company’s SEC filings for a comprehensive risk assessment.
Conclusion
Phathom Pharmaceuticals has delivered a quarter of record revenue, strong prescription growth, and its first operating profit (ex-stock comp), while continuing to advance its clinical pipeline and manage expenses. The company’s slightly reduced revenue guidance is offset by operational achievements and upcoming clinical catalysts, making this update significant for shareholders and likely to impact the company’s share price.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The article is based on the company’s official filings and statements as of July 30, 2026, and may include forward-looking statements subject to risks and uncertainties.
